Celldex Therapeutics, INC Form 4 insider transactions

Teri Lawver, SVP & Chief Commercial Officer at Celldex Therapeutics, was granted 90,000 incentive stock options.

Celldex Therapeutics reports the grant of incentive stock options to SVP & General Counsel Freddy A. Jimenez.

Diane C. Young, SVP and Chief Medical Officer of Celldex Therapeutics, was granted incentive stock options for 57,000 shares.

Celldex Therapeutics reports the grant of incentive stock options to SVP of Regulatory Affairs, Margo Heath-Chiozzi.

Celldex Therapeutics SVP and CFO, Samuel Bates Martin, was granted stock options for 93,000 shares of common stock.

Celldex Therapeutics reports an executive, Sarah Cavanaugh, received an incentive stock option grant for 95,000 shares.

Celldex Therapeutics reports that SR. VP & CPDO Elizabeth Crowley was granted incentive stock options for 100,000 shares.

Celldex Therapeutics reports that Senior VP & Chief Business Officer Ronald Pepin was granted 20,000 incentive stock options.

Celldex Therapeutics Executive VP & CSO, Tibor Keler, was granted 115,000 incentive stock options with an exercise price of $34.09.

Celldex Therapeutics President & CEO Anthony S. Marucci acquired 375,000 incentive stock options with an exercise price of $34.09.

Celldex Therapeutics reports a stock option grant to Director Denice Torres, with an exercise price of $34.09.

Celldex Therapeutics reports a Form 4 filing detailing the acquisition of stock options by Director Rita Jain.

Celldex Therapeutics, Inc. reports the grant of non-qualified stock options to Director Garry Arthur Neil.

Celldex Therapeutics reports the grant of stock options to Director Cheryl Cohen under the company's 2021 Omnibus Equity Incentive Plan.

Celldex Therapeutics Director Keith L. Brownlie was granted stock options for 26,000 shares of common stock.

Celldex Therapeutics Director James J. Marino acquired 26,000 stock options under the company's 2021 Omnibus Equity Incentive Plan.

Celldex Therapeutics Director Herbert J. Conrad acquired 26,000 stock options under the company's 2021 Omnibus Equity Incentive Plan.

Celldex Therapeutics reports that Director Harry Penner Jr. was granted 26,000 non-qualified stock options.

Celldex Therapeutics' SVP and CFO, Samuel Bates Martin, exercised stock options to acquire 4,817 shares of common stock.

Ronald Pepin, Celldex Therapeutics' SR. VP & CBO, exercised stock options for 19,333 shares of common stock on December 15, 2025.

Celldex Therapeutics' SVP & General Counsel, Freddy A. Jimenez, sold 4,166 shares of common stock for $29.095 per share under a pre-arranged 10b5-1 plan.

Richard M. Wright, a former officer of Celldex Therapeutics, Inc., executed a series of option exercises and subsequent share sales on November 13, 2025.

Celldex Therapeutics' SVP & Chief Commercial Officer, Teri L Lawver, was granted 100,000 incentive stock options with an exercise price of $22.67.

Celldex Therapeutics' SVP & General Counsel, Freddy A. Jimenez, sold 771 shares of common stock through a pre-arranged trading plan.

Celldex Therapeutics' Senior Vice President of Corporate Affairs & Administration, Sarah Cavanaugh, was granted 78,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, Inc., was granted 85,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Margo Heath-Chiozzi, SVP of Regulatory Affairs at Celldex Therapeutics, was granted 82,000 incentive stock options with an exercise price of $19.53, vesting over four years.

Celldex Therapeutics, Inc. has granted 75,000 incentive stock options to its SVP & General Counsel, Freddy A. Jimenez, under its 2021 Omnibus Equity Incentive Plan.

Celldex Therapeutics' Senior Vice President and Chief Financial Officer, Samuel Bates Martin, was granted 81,000 incentive stock options with a vesting schedule extending through 2029.

Ronald Pepin, Senior Vice President and Chief Business Officer of Celldex Therapeutics, Inc., was granted 20,000 incentive stock options with an exercise price of $19.53, vesting over four years.